Literature DB >> 8747084

Autoantibodies to Auerbach's plexus in achalasia.

W B Storch1, V F Eckardt, M Wienbeck, T Eberl, P G Auer, A Hecker, T Junginger, H Bosseckert.   

Abstract

Achalasia is a motor disorder of the oesopagus characterized by decrease in ganglion cell density in Auerbach's plexus. The cause of the lesion is unknown. This is to repeat on the occurrence of autoimmune phenomena in patients with achalasia, in particular circulating antibodies against Auerbach's plexus and its possible meaning. IgG-antibodies against Auerbach's plexus were determined by standard indirect immunofluorescence. Antibodies to the cytoplasm of Auerbach's plexus were found in 37 of 58 patients with achalasia at variable stages of the disease (I-IV) with a disease duration ranging from 1 to 20 years but only in 4 out of 54 healthy controls (specificity 93%, sensitivity 64%, p < 0.0001), and in none of 12 patients with Hirschsprung's disease as well as 12 patients with cancer of oesophagus and only in one of 11 patients with peptic oesophagitis as well as in one of 13 patients with myasthenia gravis. The present observations suggest that autoimmunity to Auerbach's plexus plays a role in the pathogenesis of achalasia, the mechanism of action is unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8747084

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  23 in total

1.  Novel mechanism for impaired nitrergic relaxation in achalasia.

Authors:  G E Boeckxstaens
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

2.  Fever, ulcers and joint pain: an incidental finding of oesophageal dysmotility.

Authors:  Charles Anwuzia-Iwegbu; Asma Fikree; Nicola Tufton
Journal:  BMJ Case Rep       Date:  2013-08-29

3.  Achalasia and thyroid disease.

Authors:  Mohammad Hassan Emami; Mostafa Raisi; Jaleh Amini; Hamed Daghaghzadeh
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 4.  Surgical treatment for achalasia: when should it be performed, and for which patients?

Authors:  Hideyuki Kashiwagi; Nobuo Omura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-06-15

5.  POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia.

Authors:  Heidi J Miller; Ruel Neupane; Mojtaba Fayezizadeh; Arnab Majumder; Jeffrey M Marks
Journal:  Surg Endosc       Date:  2016-08-17       Impact factor: 4.584

Review 6.  2011 update on esophageal achalasia.

Authors:  Seng-Kee Chuah; Pin-I Hsu; Keng-Liang Wu; Deng-Chyang Wu; Wei-Chen Tai; Chi-Sin Changchien
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

7.  Serum from achalasia patients alters neurochemical coding in the myenteric plexus and nitric oxide mediated motor response in normal human fundus.

Authors:  S Bruley des Varannes; J Chevalier; S Pimont; J-C Le Neel; M Klotz; K-H Schafer; J-P Galmiche; M Neunlist
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

8.  Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease.

Authors:  P L Moses; L M Ellis; M R Anees; W Ho; R I Rothstein; J B Meddings; K A Sharkey; G M Mawe
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 9.  The management of esophageal achalasia: from diagnosis to surgical treatment.

Authors:  Adrian Dobrowolsky; P Marco Fisichella
Journal:  Updates Surg       Date:  2013-07-02

10.  Esophageal achalasia: is the herpes simplex virus really innocent?

Authors:  Ignazio Castagliuolo; Paola Brun; Mario Costantini; Christian Rizzetto; Giorgio Palù; Michela Costantino; Nicola Baldan; Giovanni Zaninotto
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.